Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress

Toxicology in Vitro

Volumn 28, Issue 2, 2014, Pages 248-257

  Valentovic, Monica A ^a   Ball, John G ^a   Mike Brown, J ^a   Terneus, Marcus V ^b   McQuade, Elizabeth ^a   Van Meter, Stephanie ^a   Hedrick, Hayden M ^a   Roy, Amy Allison ^a   Williams, Tierra ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Formulation Development Services   (India)

Author keywords

4 Hydroxynonenal; Cisplatin; Nephrotoxicity; Oxidative stress; Resveratrol

Indexed keywords

4 HYDROXYNONENAL; CARBONYL DERIVATIVE; CISPLATIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; RESVERATROL; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; KIDNEY SLICE; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; RAT; RENAL PROTECTION;

2,4-DINITROPHENYLHYDRAZINE; 2,4-DINITROPHENYLHYDRAZONE; 4-HNE; 4-HYDROXYNONENAL; ANALYSIS OF VARIANCE; ANOVA; CISPLATIN; DNP; DNPH; GLUTATHIONE; GSH; LACTATE DEHYDROGENASE; LDH; MALONDIALDEHYDE; MDA; MRP2; MULTIDRUG RESISTANCE PROTEIN 2; NEPHROTOXICITY; OXIDATIVE STRESS; RES; RESVERATROL; VEH; VEHICLE;

ALDEHYDES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; CELL SURVIVAL; CISPLATIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; KIDNEY; KIDNEY DISEASES; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, INBRED F344; STILBENES; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84889585093     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.11.001     Document Type: Article

References (45)

1. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24(5A):2783-27840.
2. Arany I., Safirstein RL. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23(5):460-464. (Toxicol. Lett. 3, 212(3): 320-8).
3. Baverel G., Knouzy B., Gauthier C., El Hage M., Ferrier B., Martin G., Duplany A. 1. Use of precision-cut renal cortical slices in nephrotoxicity studies. Xenobiotica 2013, 43(1):54-62.
4. Berndt W.O. Use of the tissue slice technique for evaluation of renal transport processes. Environ. Health Perspect. 1976, 15:73-88.
5. Brouwers E.E.M., Huitema A.D.R., Beijnen J.H., Schellens J.H.M. Long term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol. 2009, 8:7. 10.1186/1472-6904-8-7.
6. Brown V.A., Patel K.R., Viskaduraki M., Crowell J.A., Perloff M., Booth T.D., Vasilinin G., Sen A., Schinas A.M., Piccirilli G., Brown K., Steward W.P., Gescher A.J., Brenner D.E. Repeat dose study of the cancer chemopreventative agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin like growth factor axis. Cancer Res. 2010, 70:9003-9011.
7. Brown J.M., Ball J.G., Wright M.S., Van Meter S., Valentovic M.A. Novel protective mechanisms for S-adenosyl-L-methionine against acetaminophen hepatotoxicity: improvement of key antioxidant enzymatic function. 2012, 212:320-328.
8. Burton C.A., Hatlelid K., Divine K., Carter D.E., Fernando Q., Brendel K., Gandolfi A.J. Glutathione effects on toxicity and uptake of mercuric chloride and sodium arsenite in rabbit renal cortical slices. Environ. Health Perspect. 1995, 103(Suppl 1):81-84.
9. Cetin R., Devrim E., Kilicoglu B., Avci A., Candir O., Durak I. Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J. Appl. Toxicol. 2006, 26(1):42-46.
10. Chu G. Cellular responses to cisplatin. J. Biol. Chem. 1994, 269:787-790.
11. Cummings B.S., Schnellmann R.G. Cisplatin induced renal cell apoptosis: caspase-3 dependent and independent pathways. J. Pharmacol. Exp. Ther. 2002, 302:8-17.
12. Dickman K.G., Sweet D.H., Bonala R., Ray T., Wu A. Physiological and molecular characterization of aristolochic acid transport by the kidney. J. Pharmacol. Exp. Ther. 2011, 338(2):588-597.
13. Do Amaral C.L., Francescato H.D.C., Coimbra T.M., Costa R.S., Darin J.D.C., Antunes L.M.G., Bianchia M.D.L.P. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch. Toxicol. 2008, 82:363-370.
14. Fujieda M., Matsunaga A., Hayashi A., Tauchi H., Chayama K., Sekine T. Children's toxicology from bench to be-drug induced renal injury (2): Nephrotoxicity inducec by cisplatin and ifosfamide in children. J. Toxicol. Sci. 2009, 34(Special issue II):SP251-SP257.
15. Groth S., Nielsen H., Sørensen J.B., Christensen A.B., Pedersen A.G., Rørth M. Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother. Pharmacol. 1986, 17(2):191-196.
16. Hambley T.W. Modelling the interaction of cisplatin with DNA. Drug Des. Deliv. 1988, 3(2):153-158.
17. Juan M.E., Maijo M., Planas J.M. Quantification of trans-resveratrol and its metabolites in rat plasma and tissue by HPLC. J. Pharm. Biomed. Anal. 2010, 51:391-398.
18. Kim J.-H., Chen C., Kong A.-N. Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch. Biochem. Biophys. 2011, 512:160-166.
19. Kintzel P.E. Anticancer drug induced - kidney disorders. Drug Safety 2001, 2001(24):19-38.
20. Lawrence R.A., Burk R.F. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem. Biophys. Res. Commun. 1976, 71:952-958.
21. Lee M.-H., Choi B.Y., Kundu J.K., Shin Y.K., Na H.-K. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a Murine Xenograft Model: Eukaryotic Elongation Factor 1A2 as a potential target. Cancer Res. 2009, 69:7449-7458.
22. Ludwig T., Riethmuller C., Gekle M., Schwerdt G., Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004, 66:196-202.
23. Meier B.W., Gomez J.D., Kirichenko O.V., Thompson J.A. Mechanistic basis for inflammation and tumor promotion in lungs of 2,6-di-tert-butyl-4-methylphenol-treated mice: electrophilic metabolites alkylate and inactivate antioxidant enzymes. Chem. Res. Toxicol. 2007, 20:199-207.
24. Ognjanovic B., Djordjevic N.Z., Obradovic J.M., Mladenovic J.M., Stajn A.S., Saicic Z.S. Lipid peroxidative damage on Cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int. J. Mol. Sci. 2012, 13:1790-1803.
25. Olas B., Wachowicz B. Resveratrol reduces oxidative stress induced by platinum compounds in blood platelets. Gen. Physiol. Biophys. 2004, 23(3):315-326.
26. Olas B., Wachowicz B., Bald E., Glowacki R. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J. Physiol. Pharmacol. 2004, 55(2):467-476.
27. Olas B., Wachowicz B., Majsterek I., Blasiak J. Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes. Anticancer Drugs 2005, 16(6):659-665.
28. Opipari A.W., Tan L., Boitano A.E., Sorenson D.R., Aurora A., Liu J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res. 2004, 64(2):696-703.
29. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
30. Park S.B., Krishnan A.V., Lin C.S., Goldstein F., Friedlander M., Kiernan M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr. Med. Chem. 2008, 15:3081-3094.
31. Patel K.R., Brown V.A., Jones D.J.L., Britton R.G., Hemingway D., Miller A.S., West K.P., Booth T.D., Perloff M., Crowell J., Brenner D., Steward W.P., Gescher A., Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70:7392-7399.
32. Petersen P.M., Hansen S.W. The course of long term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Annals Oncol. 1999, 10:1475-1483.
33. Ramesh G., Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002, 110:835-842.
34. Ramesh G., Reeves W.B. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am. J. Physiol. Renal. Physiol. 2003, 285:F610-F618.
35. Rezk Y.A., Balulad S.S., Keller S., Bennett J.A. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J. Obstet. Gynecol. 2006, 194:e23-e26.
36. Ricart A.D., Berlin J.D., Papadopoulos K.P., Syed S., Drolet D.W., Quaratino-Baker C., Horan J., Chick J., Vermeulen W., Tolcher A.W., Rowinsky E.K., Rothenberg M.L. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin. Cancer Res. 2008, 14(23):947-955.
37. Rimando A.M., Kalt W., Magee J.B., Dewey J., Ballington J.R. Resveratrol, Pterostilbene and Piceatannol in Vaccinium Berries. J. Agric. Food Chem. 2004, 52:4713-4719.
38. Selles B., Hugo M., Trujillo M., Srivastava V., Wingsle G., Jacquot J.P., Radi R., Rouhier N. Hydroperoxide and peroxynitrite reductase activity of poplar thioredoxin-dependent glutathione peroxidase 5: kinetics, catalytic mechanism and oxidative inactivation. Biochem. J. 2012, 442:369-380.
39. Ulrich S., Wolter R., Stein J.M. Molecular mechanisms of the chemoperventive effects of resveratrol and its analogs in carcinogenesis. Mol. Nutr. Food Res. 2005, 49:452-461.
40. Urien S., Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br. J. Clin. Pharmacol. 2004, 57:756-763.
41. Valentovic M.A., Scott L.A., Madan E., Yokel R.A. Renal accumulation and urinary excretion of cisplatin in diabetic rats. Toxicology 1991, 70:151-162.
42. Valentovic M.A., Ball J.G., Hong S.K., Rogers B.A., Meadows M.K., Harmon R.C., Rankin G.O. In vitro toxicity of 2- and 4-chloroaniline: comparisons with 4-amino-3-chlorophenol, 2-amino-5-chlorophenol and aminophenols. Toxicol. In Vitro 1996, 10:713-720.
43. Valentovic M.A., Ball J.G., Sun H., Rankin G.O. Characterization of 2-amino- 4,5- dichlorophenol (2A45CP) in vitro toxicity in renal cortical slices from male fischer 344 rats. Toxicology 2002, 172(2):113-123.
44. Van Ginkel P.R., Sareen D., Subramanian L., Walker Q., Darjatmoko S.R., Lindstrom M.J., Kulkarni A., Albert D.M., Polans A.S. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin. Cancer Res. 2007, 13(17):5162-5169.
45. 14C-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003, 72:2219-2233.